Your browser doesn't support javascript.
loading
Mechanisms of hepatocellular carcinoma progression.
Ogunwobi, Olorunseun O; Harricharran, Trisheena; Huaman, Jeannette; Galuza, Anna; Odumuwagun, Oluwatoyin; Tan, Yin; Ma, Grace X; Nguyen, Minhhuyen T.
Afiliação
  • Ogunwobi OO; Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, United States.
  • Harricharran T; Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, United States.
  • Huaman J; Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, United States.
  • Galuza A; Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, United States.
  • Odumuwagun O; Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, United States. ogunwobi@genectr.hunter.cuny.edu.
  • Tan Y; Center for Asian Health, School of Medicine, Temple University, Philadelphia, PA 19140, United States.
  • Ma GX; Center for Asian Health, School of Medicine, Temple University, Philadelphia, PA 19140, United States.
  • Nguyen MT; Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
World J Gastroenterol ; 25(19): 2279-2293, 2019 May 21.
Article em En | MEDLINE | ID: mdl-31148900
ABSTRACT
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells, immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: World J Gastroenterol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: World J Gastroenterol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos